BR112023019689A2 - Terapias multifuncionais de célula imunológica - Google Patents
Terapias multifuncionais de célula imunológicaInfo
- Publication number
- BR112023019689A2 BR112023019689A2 BR112023019689A BR112023019689A BR112023019689A2 BR 112023019689 A2 BR112023019689 A2 BR 112023019689A2 BR 112023019689 A BR112023019689 A BR 112023019689A BR 112023019689 A BR112023019689 A BR 112023019689A BR 112023019689 A2 BR112023019689 A2 BR 112023019689A2
- Authority
- BR
- Brazil
- Prior art keywords
- car
- multifunctional
- adapter
- immune cell
- cell therapies
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title abstract 2
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166550P | 2021-03-26 | 2021-03-26 | |
| PCT/US2022/021633 WO2022204340A1 (en) | 2021-03-26 | 2022-03-24 | Multifunctional immune cell therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019689A2 true BR112023019689A2 (pt) | 2023-10-31 |
Family
ID=83396077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019689A BR112023019689A2 (pt) | 2021-03-26 | 2022-03-24 | Terapias multifuncionais de célula imunológica |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4313083A1 (es) |
| JP (1) | JP2024512590A (es) |
| KR (1) | KR20230162957A (es) |
| CN (1) | CN117425484A (es) |
| AU (1) | AU2022242842A1 (es) |
| BR (1) | BR112023019689A2 (es) |
| CA (1) | CA3212948A1 (es) |
| IL (1) | IL306096A (es) |
| MX (1) | MX2023011110A (es) |
| WO (1) | WO2022204340A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7356435B2 (ja) | 2017-11-14 | 2023-10-04 | アーセルクス インコーポレイテッド | 多機能性免疫細胞療法 |
| WO2023086983A1 (en) | 2021-11-15 | 2023-05-19 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7285267B2 (ja) * | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Ｄドメイン含有ポリペプチドおよびその使用 |
| JP7356435B2 (ja) * | 2017-11-14 | 2023-10-04 | アーセルクス インコーポレイテッド | 多機能性免疫細胞療法 |
-
2022
- 2022-03-24 IL IL306096A patent/IL306096A/en unknown
- 2022-03-24 MX MX2023011110A patent/MX2023011110A/es unknown
- 2022-03-24 WO PCT/US2022/021633 patent/WO2022204340A1/en active Application Filing
- 2022-03-24 AU AU2022242842A patent/AU2022242842A1/en active Pending
- 2022-03-24 KR KR1020237036708A patent/KR20230162957A/ko unknown
- 2022-03-24 JP JP2023558745A patent/JP2024512590A/ja active Pending
- 2022-03-24 CN CN202280037802.2A patent/CN117425484A/zh active Pending
- 2022-03-24 BR BR112023019689A patent/BR112023019689A2/pt unknown
- 2022-03-24 CA CA3212948A patent/CA3212948A1/en active Pending
- 2022-03-24 EP EP22776612.8A patent/EP4313083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4313083A1 (en) | 2024-02-07 |
| CN117425484A (zh) | 2024-01-19 |
| MX2023011110A (es) | 2023-11-23 |
| AU2022242842A1 (en) | 2023-10-05 |
| CA3212948A1 (en) | 2022-09-29 |
| JP2024512590A (ja) | 2024-03-19 |
| IL306096A (en) | 2023-11-01 |
| WO2022204340A1 (en) | 2022-09-29 |
| KR20230162957A (ko) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019689A2 (pt) | Terapias multifuncionais de célula imunológica | |
| MX2020004935A (es) | Terapias con celulas inmunitarias multifuncionales. | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
| BR112015000638A2 (pt) | sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor | |
| MX2019001185A (es) | Polipeptidos inmunomoduladores y composiciones y metodos relacionados. | |
| CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
| BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
| BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
| BR112013014265B8 (pt) | Molécula de ácido nucleico isolada, receptor antígeno quimérico isolado, e, vetor | |
| BR112014006176A2 (pt) | rna transcrito in vitro ou rna sintético, célula t, e, métodos para gerar uma população de células t geneticamente modificadas por rna, e para tratar um paciente com cancer | |
| BR112015000657A8 (pt) | uso de uma célula geneticamente modificada para expressar um car. | |
| BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
| BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
| BR112021026382A2 (pt) | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer | |
| BR112013012555B8 (pt) | Peptídeo imunogênico isolado derivado de uma proteína antigênica, seus usos, método para a preparação de um peptídeo com capacidade de provocar a ativação de células nkt e método in vitro para obtenção de uma população de células nkt cd4+ antígeno específicas | |
| BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 | |
| BR112022005423A2 (pt) | Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap) | |
| BR112021019772A2 (pt) | Reconstituição de cd3 em células efetoras imunes e ipsc geneticamente modificadas | |
| BR112021024822A2 (pt) | Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência | |
| BR112021020867A2 (pt) | Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração | |
| BR112022009204A2 (pt) | Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 | |
| BR112021021542A2 (pt) | Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19 | |
| BR112022009141A2 (pt) | Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70 | |
| CO2022009086A2 (es) | Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos |